Navigation Links
Jazz Pharmaceuticals Announces Stockholder Vote in Favor of Transaction With Azur Pharma Limted
Date:12/12/2011

PALO ALTO, Calif., Dec. 12, 2011 /PRNewswire/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced that the Jazz Pharmaceuticals stockholders have approved all of the proposals submitted for approval at today's stockholder meeting, including the proposal  to approve the combination of the businesses of Jazz Pharmaceuticals and Azur Pharma. Once the transaction is closed, the Jazz Pharmaceuticals and Azur Pharma businesses will operate as a combined company, Jazz Pharmaceuticals plc, a company domiciled in Ireland.

Approximately 99.86% of the votes cast by Jazz Pharmaceuticals' stockholders were cast in favor of the merger agreement. Jazz Pharmaceuticals currently anticipates that the transaction will close in January 2012. Following the closing, Jazz Pharmaceuticals plc will be listed on the Nasdaq stock exchange under Jazz Pharmaceuticals' current ticker symbol, "JAZZ."

The merger will result in a specialty biopharmaceutical company with a diversified revenue base from 12 marketed products in the areas of CNS and women's health. These include Xyrem® (indicated to treat the two key symptoms of narcolepsy), Luvox CR® (indicated to treat obsessive compulsive disorder), Prialt® (indicated for refractory severe chronic pain), FazaClo® (indicated for treatment resistant schizophrenia), two additional CNS products and a portfolio of women's health products led by Elestrin® (for vasomotor symptoms associated with menopause). Full prescribing information about each product is available through its individual product website.

"We view the outstanding stockholder support in favor of the merger agreement as emphasizing both the short- and long-term benefits of combining forces with Azur to create a dynamic specialty biopharmaceutical company," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. "As an integ
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015 ... Analyzers Market by Product (Bioimpedance Analyzers (BIA), Dual-Energy X-ray ... Hydrostatic Weighing) - Global Analysis & Forecast to 2019", ... was pegged at $911.1 Million 2014 and is estimated ... a CAGR of 9.4% from 2014 to 2019. ...
(Date:7/30/2015)... July 30, 2015  ResMed (NYSE: ... a definitive agreement to acquire Curative Medical, ... and sleep-disordered breathing medical devices and accessories. ... in China, combined with ResMed,s global leadership in sleep and respiratory ... China suffering from sleep-disordered ...
(Date:7/30/2015)... 2015  EP Global Communications, Inc. (Public OTC: EPGL) announced ... the Company about discussing EPGL,s electronic contact lens ... August 3, 2015.  Novartis CEO Joe Jimenez ... coming electronic contact lens market could be worth ... several years.  Novartis partnered with Google in 2014 ...
Breaking Medicine Technology:Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3
... Inc.,(Nasdaq: MEDX ) announced today interim ... hormone refractory prostate cancer (HRPC) demonstrating,dose-dependent T-cell ... anti-CTLA-4 antibody. These studies were done in,combination ... that stimulates the proliferation of white blood ...
... GAITHERSBURG, Md., April 15 MedImmune today announced,that ... a potential treatment,for patients with asthma, with the ... (MAb) targeting interleukin-13 (IL-13). One of the,studies is ... Australia designed to,assess the potential of the anti-IL-13 ...
Cached Medicine Technology:Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting 2Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting 3Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting 4MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13 2MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13 3
(Date:8/1/2015)... ... ... Phil Valentine – the Executive Director of Connecticut Community for Addiction Recovery (CCAR) – began ... and heading north. Since that day, Phil has hiked over 1400 miles in nine states. ... family. He visited CCAR and left an inspirational message to his staff: “You can ...
(Date:7/31/2015)... ... ... Bowl 50 will emanate from Levi’s Stadium in Santa Clara, CA on Sunday, February ... In the two weeks that separate the conference championships and the Super Bowl, there is ... will mark the 50th time it has been held and the festivities will take place ...
(Date:7/31/2015)... ... , ... The 2nd annual Ride to Fight On will start and end ... The Ride to Fight On is a cycling fundraiser that benefits the West Cancer ... and The University of Tennessee Health Science Center. A health and wellness festival featuring ...
(Date:7/31/2015)... Mountain View, CA (PRWEB) , ... July 31, 2015 , ... ... hand for the athletes, judges, media, and VIPs at the 2015 Vans US Open ... best-tasting organic coconut water that can claim “no added sugar” on the market, is ...
(Date:7/31/2015)... ... 2015 , ... Well-known for its unique pastries and delicious confections, Pastry Palace, ... designs, making life just a little bit sweeter for newlyweds. A family-owned business, the ... orders one. , The bakery provides a full line of custom wedding cakes. Brides ...
Breaking Medicine News(10 mins):Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2
... use of dexamethasone early in the treatment of children ... childhood cancer, may help reduce the risk of relapse ... conference on Saturday, December 6, at 2:00 p.m., during ... Hematology in San Francisco, CA. Additional research will be ...
... Dec. 6 Purple Cowboy is a new wine that will,help ... National,Finals Rodeo in Las Vegas this month. , ... combination, but in terms of the,professional rodeo community,s commitment to end ... This year, Las Vegas will host the ultimate championship of ...
... Dutch Health Insurance System model, according to an article by ... Journal of Health Politics, Policy and Law . , ... University of Texas School of Public Health at Houston, co-authored ... the Netherlands and its possible lessons for the United States. ...
... many tumors can be left untreated, depending on man,s age ... prostate cancer may prompt an understandable feeling of dread, but ... disposal for tackling the disease, medical experts say. , There ... should be considered strongly when weighing various procedures. In fact, ...
... Dec. 5 Two new studies out this week add to ... associated with increased risk of adverse mental health effects. The two ... and the Journal of Psychiatric Research . Both had ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20080930/FRCLOGO ...
... understand the connection , , FRIDAY, Dec. 5 (HealthDay News) ... mental health and your respiratory health -- specifically asthma. ... were more likely to have asthma than those who ... report. , If you,re a person with both asthma ...
Cached Medicine News:Health News:Novel treatments show improvements in survival and response rates for leukemia and lymphoma 2Health News:Novel treatments show improvements in survival and response rates for leukemia and lymphoma 3Health News:Novel treatments show improvements in survival and response rates for leukemia and lymphoma 4Health News:Novel treatments show improvements in survival and response rates for leukemia and lymphoma 5Health News:Novel treatments show improvements in survival and response rates for leukemia and lymphoma 6Health News:The Days of Wine and Rodeo 2Health News:UT public health policy expert says US can learn from Dutch universal healthcare coverage 2Health News:Treatment Options Are Many for Prostate Cancer 2Health News:Treatment Options Are Many for Prostate Cancer 3Health News:Poor Mental Health May Boost Asthma Risk 2
... provides a versatile means of sectioning fresh ... The 1000 employs a vibrating blade principle ... The creation of artifacts, the alteration ... and other deleterious effects inherent in freezing ...
... The NEW Vibratome 3000 Deluxe Sectioning ... fresh or fixed, animal, or plant tissues. ... principle which allows sectioning without freezing or ... alteration of morphology, the destruction of enzyme ...
... The NEW Vibratome 3000 Plus Sectioning ... fresh or fixed, animal, or plant tissues. ... principle which allows sectioning without freezing or ... alteration of morphology, the destruction of enzyme ...
... The Vibratome 1000 Plus Sectioning System ... or fixed, animal, or plant tissues. ... which allows sectioning without freezing or embedding. ... of morphology, the destruction of enzyme activities, ...
Medicine Products: